2020 IPO

Poseida Therapeutics Stock

Genome engineering-enabled therapeutics

Sign up today and learn more about Poseida Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Poseida Therapeutics Stock

Poseida Therapeutics is a spin out of Transposagen Biopharmaceuticals that utilizes best-in-class, proprietary genome editing technologies to develop targeted, life-saving therapeutics in areas of high unmet medical need. It has demonstrated proof-of-principle that validates the potential of its differentiated genome engineering technologies and their therapeutic applications. The company's technology platforms have broad applicability and Poseida’s long-term goal is to apply its proprietary gene editing technologies to a broad range of human diseases.

Funding History

December 2015$23.0M
August 2017$11.2M
October 2017$19.8M
April 2018$30.5M
April 2019$142M


Chief Technology Officer

Paiman Peter Ghoroghchian

Chief Executive Officer

Eric Ostertag

Chief Medical Officer

Matthew Spear

Chief Human Resources Officer

Kristin Martin

President and Chief Operating Officer

Nishan de Silva

Chief Business Officer and Chief Financial Officer

Mark J. Gergen

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: